Roche licenses GKA diabetes candidates to China's Hua Medicine
This article was originally published in Scrip
The Shanghai, China-based drug development company Hua Medicine has signed a licensing agreement giving it exclusive development, manufacturing and global sales and marketing rights to a series of novel small molecule activators of the glucokinase enzyme developed by Roche, including RO5305553, which have the potential to lower elevated blood glucose levels in diabetes patients.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.